HUMACYTE INC. - COMMON STOCK

Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients

11 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

24 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023

21 Mar 2023 08:01:00 By Nasdaq GlobeNewswire

Humacyte to Present at Upcoming Investor Conferences in March

27 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease

24 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime

13 Dec 2022 08:00:02 By Nasdaq GlobeNewswire

Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022

01 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference

23 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Humacyte Third Quarter 2022 Financial Results and Business Update

10 Nov 2022 07:00:04 By Nasdaq GlobeNewswire

Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting

07 Nov 2022 08:01:12 By Nasdaq GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022

03 Nov 2022 08:00:04 By Nasdaq GlobeNewswire

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting

23 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Humacyte Expands Board of Directors and Leadership Team with New Appointments

20 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress

09 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Humacyte Presents at Multiple Conferences in September 2022

08 Sep 2022 08:01:00 By Nasdaq GlobeNewswire

Humacyte Second Quarter 2022 Financial Results and Business Update

12 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022

05 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting

25 Jul 2022 20:26:26 By Nasdaq GlobeNewswire

Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions

19 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

07 Jul 2022 08:00:01 By Nasdaq GlobeNewswire